Cartalax

Quickstart Highlights

Cartalax is a synthetic tripeptide bioregulator (Ala‑Glu‑Asp; sequence “AED”) developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Preclinical studies indicate it may modulate fibroblast proliferation markers (Ki‑67), reduce pro‑apoptotic signaling (p53, caspase‑3), and support extracellular matrix homeostasis. Note: Published human posology for subcutaneous Cartalax is limited; this framework extrapolates from available preclinical and observational data for educational purposes only.

• Reconstitute: Add 2.0 mL bacteriostatic water (BAC) per labelled 20 mg vial. Calculations assume a final volume of 2.0 mL and nominal 10 mg/mL.
• Example daily range: 1–4 mg once daily for a 10–20 day course (1 mg for Days 1–3, then 2 mg; 4 mg is the upper limit for larger or advanced users); repeat 2–3 times per year, at least 3 months apart.
• Scale conversion: At 10 mg/mL, 1 U-100 unit = 0.01 mL = 0.1 mg (100 mcg). Verify the actual device markings and calibration.
• Storage: Lyophilized: store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the 20-day course regimen.

• Goal: Support connective‑tissue homeostasis and fibroblast function based on preclinical bioregulator research.
• Schedule: One daily subcutaneous injection for a 10–20 day course (10-day short course, 20-day standard); repeat two to three times per year with at least 3 months between courses.
• Dose Range: 1–4 mg daily; 1 mg for Days 1–3, then 2 mg. 4 mg is the upper limit for larger or advanced users.
• Reconstitution: 2.0 mL BAC per labelled 20 mg vial; nominal 10 mg/mL under the stated final-volume assumption.
• Storage: Lyophilized: refrigerate or freeze; reconstituted: refrigerate; avoid repeated freeze–thaw.

Dosing Protocol

Suggested 10–20 day course (Khavinson-style bioregulator schedule; 20 days standard).

• Start: 1,000 mcg (1 mg) daily for Days 1–3 to assess tolerance.
• Target: 2,000 mcg (2 mg) daily from Day 4 through Day 20.
• Frequency: Once per day (subcutaneous).
• Course Length: 10–20 days (10-day short course, 20-day standard); 2–3 courses per year with at least 3 months between courses. Do not extend continuously.
• Timing: Any consistent time; rotate injection sites daily.
• Upper limit: 4,000 mcg (4 mg) daily for larger or advanced users; do not exceed.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term stability; protect from light and moisture.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Evidence caveat: Published human clinical trial data for subcutaneous Cartalax is limited; this protocol extrapolates from preclinical studies and standard peptide handling practices.

How This Works

Cartalax (Ala‑Glu‑Asp) is classified among the Khavinson bioregulatory peptides—ultrashort peptides that may interact with DNA and modulate gene expression at nanomolar concentrations. The peptide sequence corresponds to a motif found in the alpha‑1 chain of type XI collagen, a structural protein important for cartilage integrity. In preclinical fibroblast and chondrocyte culture models, Cartalax has been reported to upregulate Ki‑67 (a proliferation marker), increase SIRT‑1/SIRT‑6 expression, reduce p53 and caspase‑3 activity (pro‑apoptotic signals), and inhibit MMP‑9 synthesis (an enzyme linked to extracellular matrix degradation).

Potential Benefits & Side Effects

Observations from preclinical literature.

• May support fibroblast proliferation and reduce markers of cellular senescence in aged cell cultures.
• Preclinical data suggest modulation of extracellular matrix homeostasis via MMP‑9 inhibition and collagen‑related gene expression.
• General tolerability: Khavinson bioregulator peptides have been described as well tolerated in observational settings; occasional mild injection‑site reactions (redness, itch) may occur with subcutaneous administration.
• Limitations: No large‑scale human RCTs; most data derive from in vitro or rodent models.

Lifestyle Factors

Complementary strategies for best outcomes.

• Support joint and connective‑tissue health with adequate protein, vitamin C, and collagen precursors.
• Combine low‑impact exercise and mobility work to reinforce musculoskeletal adaptations.
• Prioritize sleep and stress management to support tissue repair and recovery.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Browse Amino Labs